VALBIOTIS news, videos and press releases - Page 2
For more news please use our advanced search feature.
VALBIOTIS - More news...
VALBIOTIS - More news...
- Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM•63: Proven Efficacy on the Main Risk Factor of Developing Type 2 Diabetes
- Valbiotis – Combined Annual Shareholders General Meeting held on May 2, 2023
- Valbiotis announces the release of the Universal Registration Document
- Valbiotis Announces Its Combined Shareholders General Meeting Will Be Held on May 2, 2023
- Valbiotis Publishes Its 2022 Annual Results and Provides an Update on Its Strategic Roadmap
- Valbiotis Announces the Last Visit of the Last Patient in the Phase II/III REVERSE-IT Study on TOTUM•63, in Partnership with Nestlé Health Science
- Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar
- Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM•854 Clinical Study, Against High Blood Pressure
- Valbiotis Announces Its Roadmap for 2023: a Pivotal Year in the Execution of Its Clinical, Industrial and Commercial Strategy
- Valbiotis Announces the Signature of a Research Partnership in Intestinal Microbiota With the MEDIS Unit From the Clermont Auvergne University
- Valbiotis Successfully Completes a Fundraise of 9.7 Million Euros
- Valbiotis Announces the Availability of an Amendment to the Universal Registration Document
- Valbiotis Will Present Significant Preclinical Results for Its Active Substance TOTUM•448 Against Fatty Liver Diseases (NAFL and NASH), at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
- Valbiotis Accelerates Its Marketing Strategy
- Valbiotis Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia
- Valbiotis Provides an Update on Its Progress and Publishes Its Financial Report for the First Half of 2022
- Frédéric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors
- Valbiotis Announces Completion of Recruitment for the Phase II/III REVERSE-IT Clinical Study With TOTUM•63 Against Prediabetes, in Partnership With Nestlé Health Science
- Valbiotis announces the major success of the Phase II HEART clinical study: the patented plant-based active substance TOTUM•070 proves its efficacy against hypercholesterolemia, a cardiovascular risk factor
- Valbiotis Announces the Release of the Universal Registration Document
- Valbiotis - Combined Shareholders General Meeting Held on May 5, 2022
- Valbiotis Announces the First Visit of the First Patient in the TOTUM•63 Mode of Action Clinical Study Conducted by the INAF1, in Partnership With Nestlé Health Science
- Valbiotis Announces its Combined Shareholders General Meeting Will Be Held on May 5, 2022
- Valbiotis Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia
- Valbiotis is Strengthening Its Commitment to CSR by Joining the United Nations Global Compact and Applying the ISO 26000 Standard
- Valbiotis Publishes Its 2021 Annual Report
- Valbiotis Announces Upcoming Organizational Changes of its Board of Directors
- Valbiotis Presents Its 2022 Financial Communication Calendar
- Valbiotis Announces Approval to Launch the Two Phase II/III INSIGHT and INSIGHT 2 Clinical Studies, the Last Step in the Development of TOTUM•854 For the Reduction of Blood Pressure
- Valbiotis - Increased Momentum in the Clinical Newsflow for Major Indications: Results Expected in 2022 for Prediabetes, Hypercholesterolemia and High Blood Pressure
